Results from the mADCS-CGIC showed @ % of citalopram participants having moderate or marked improvement from baseline compared with @ % of placebo recipients , with estimated treatment effect ( odds ratio -LSB- OR -RSB- of being at or better than a given CGIC category ) of @ ( @ % CI , @-@ @ ) , P = @ .